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understood. Herein, we highlight a possible association between OS and 
aberrant AS events and its interaction with the expression of LEPROT. 
We also discuss the role of LEPROT in regulating growth hormone and its 
receptor, and the relationship with initiation and progression of OS. This 
research study may help to understand the association of AS mechanism 
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Alternative splicing (AS) of RNA is an essential mechanism that increases proteomic diversity in 
eukaryotic cells. Aberrant AS is often associated with various human diseases, including cancer. 
We conducted whole-transcriptome analysis of 18 osteosarcoma (OS) bone samples (paired 
normal - tumour biopsies). Using RNA-seq, we identified statistically significant (FDR <0.05) 
26 differentially expressed transcript variants of leptin receptor overlapping transcript (LEPROT) 
gene. Some of the transcripts were overexpressed in normal cells, whereas others were 
overexpressed in tumour cells. The function of LEPROT is not completely understood. Herein, 
we highlight a possible association between OS and aberrant AS events and its interaction with 
the expression of LEPROT. We also discuss the role of LEPROT in regulating growth hormone 
and its receptor, and the relationship with initiation and progression of OS. This research study 
may help to understand the association of AS mechanism in OS and in tumorigenesis more 
generally. Further, LEPROT gene can also be considered as a potential biomarker of OS.  
Keywords: Osteosarcoma, transcriptome, LEPROT, RNA sequencing, alternative splicing, 
osteogenic sarcoma
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Osteosarcoma (OS, also known as osteogenic sarcoma) is the most common primary malignancy 
of bone in children and adolescents. The molecular mechanisms of OS are extremely 
complicated and its molecular mediators remain to be elucidated. We sequenced total RNA from 
18 OS bone samples (paired normal - tumour biopsies). We found statistically significant (FDR 
<0.05) 26 differentially expressed transcript variants of LEPROT gene with different expressions 
in normal and tumour samples. These findings contribute to the understanding of molecular 
mechanisms of OS development and provide encouragement to pursue further research.
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Osteosarcoma (OS) is the most common primary tumour of bone in children and adolescents, 
with a second peak in incidence in people over the age of 50.1, 2 OS is characterised by the 
presence of malignant mesenchymal stem cells (MSCs) producing immature bone matrix or 
osteoid.3 OS commonly develops in long bones such as the distal femur, proximal tibia or 
proximal humerus.4 Patients usually present with pain and swelling. The diagnosis is confirmed 
by histology and staging studies such as MRI and systemic radionuclide scans.5-7 Current 
treatment of OS, a combination of surgery and chemotherapy (doxorubicin, methotrexate, and 
cisplatin), has improved outcomes significantly, although this regime is still only successful in 
90% of patients.8 The precise underlying mechanism of OS remains obscure in most individuals, 
however, the risk of developing OS is influenced by bone turnover, age, environment (drug or 
radiation therapy), other bone diseases (such as Paget’s disease), genetic alterations and 
hormonal regulation of puberty (such as growth hormone).9-13  
RNA sequencing (RNA-Seq) technology is a powerful tool to analyse the transcriptome of a 
cell.14 Gene expression studies have been traditionally carried out by northern blot and 
quantitative polymerase chain reaction (qPCR), which are limited to single transcript 
expressions.15, 16 The RNA-seq technique provides higher resolution of the dynamic nature of the 
transcriptome.15, 17 Beyond measuring gene expression, this technique facilitates the discovery of 
novel transcripts, identification of alternative (differential) splicing (AS) events in genes and 
detection of allele-specific expression on a genome-wide scale.15-18 Consequently, RNA-seq is a 
useful method for interpreting the functional elements of the genome and also understanding the 
underlying mechanisms of complex diseases in a species.19, 20 AS is a crucial mechanism that 
generates proteomic diversity in eukaryotes.19 It is mainly regulated by cis-acting elements and 
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trans-acting factors.21 Growing evidence suggests that more than 90% of multi-exon genes 
undergo AS in humans.22, 23 Deregulation of AS programming can produce a variety of transcript 
isoforms with unique protein-coding and possibly different or antagonistic biological functions 
from the same gene.24, 25 Predictably, abnormal splicing can disturb normal cellular physiology 
and eventually lead to diseases, including cancer.23-26 The involvement of AS in each of the 
widely recognised and accepted hallmarks of cancer has been investigated.27 In particular, 
apoptosis and metastasis are directly affected by AS.28 Moreover, it can also play an essential 
role in invasiveness, angiogenesis and chemo/radio-resistance to therapy.28, 29 
Little is known about the underlying molecular mechanism of AS in various cancer types, 
especially in OS. To improve our understanding of the genetic mechanisms involved in 
developing OS, we performed RNA-Seq transcriptome analysis from 18 normal - tumour pairs of 
bone biopsies by computational bioinformatics. Differential exon usage was studied to highlight 
AS and transcription events present between normal and tumour samples using the DEXSeq 
package. Another aim of this study was to identify potential molecular biomarkers and novel 
therapeutic target candidates for the early detection and treatment of OS.
Materials and Methods
Samples collection
The study was investigated and approved by the Ethics Review Committee on Biomedical 
Research of Hue University of Medicine and Pharmacy. The participants and patient 
representatives signed and dated the informed consent forms before surgery. 
Normal and cancerous bone samples were collected directly after surgery (limb sparing or 
amputation) from eighteen Vietnamese patients who, previously, had histological confirmation 
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of OS. The collected biopsies were replaced on dry ice and stored at -80oC until processed for 
RNA extraction.
Total RNA isolation from bone biopsies
Approximately fifty milligrams of bone sample was ground with liquid nitrogen in a pestle and 
mortar and pre-TRIzol treatment was performed (Invitrogen Corp., Carlsbad, CA, USA). RNeasy 
Fibrous Tissue Mini Kit (Qiagen Inc., Valencia CA, USA) was used to isolate total RNA from 
bone tissue following the manufacturer’s protocol. Isolated RNA was completely dissolved in 
RNase-free water and stored at -80oC. The quality of total RNA was determined by Agilent 2100 
Bioanalyzer system and the RNA 6000 Nano Kit (Agilent Technologies Inc., CA, USA). 
Fifty nanograms of total RNA was amplified using Ovation RNA-Seq System V2 (NuGen, 
Emeryville, CA, USA) and the resulting cDNAs were pooled in equal amounts. The pooled 
cDNA was used to prepare the DNA fragment library using SOLiD System chemistry (Life 
Technologies Corp, Carlsbad, CA, USA). Sequencing was done by SOLiD 5500W platform and 
DNA sequencing chemistry (Life Technologies Corp., Carlsbad, CA, USA). Raw data (75 bp) 
were colour-space mapped to the human genome hg38 (GRCH38) reference through the 
mapping algorithm implemented in the Lifescope™ Genomic Analysis software (Life 
Technologies Corp.). The mapping confidence had been noted as higher than 90 due to the 
quality threshold was set to 10. The reads scores below than 10 were filtered out. Mapping 
quality was at average of 30. Annotation of the reads based on the gencode v22 files.30 
Statistical data analyses were performed through the DEXseq package for R.31 DEXseq is a 
Bioconductor package specifically designed to find differential exon usage (DEU) based on 
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RNA-seq data. DEU describes the relative usage of exons induced by the experimental 
conditions.32 
More details on data pre-processing can be found here 
(https://bioconductor.org/packages/release/bioc/vignettes/DEXSeq/inst/doc/DEXSeq.html). 
The DEXseq package also performs sample comparison and adjusts the P-value to overcome 
multiple testing problems.33-35 Through DEXseq package, the Benjamini-Hochberg procedure 
used to control the false discovery rate (FDR).36
Results
Patient characteristics 
Paired samples (normal - tumour) of surgical biopsies of bone were collected from 18 
Vietnamese OS patients. Diagnosis was confirmed by a pathologist by examination of the 
biopsies. Tumour sites were located in the femur (55.56%), tibia (33.33%) and humerus 
(11.11%). Patient age ranged from 7 to 52 years (mean=18 years) and there were 7 females and 
11 males. Patients’ demographic and clinical characteristics are listed in Table 1.
Validation of differential exon usage of LEPROT in patient samples
A Mean-Average (MA)-plot of the log2 fold change of all transcripts (over 4075 transcripts) 
expressed in normal and tumour samples is presented in Figure 1. Red points indicate the log 
fold change versus average normalised count per exon (FDR < 0.05), whereas red triangles 
represent exons expressed with log2-fold change greater than 2 or less than −2. 
The purpose of the study was to investigate AS events between 18 paired normal-tumour OS 
samples by RNA-seq. As shown in Figure 2A, statistically significant (FDR < 0.05) changes in 
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expression levels of Leptin Receptor Overlapping Transcript (LEPROT) exons were observed 
between normal and tumour samples. Most of the exons are expressed in normal tissue, while 
expression in the tumour sample remained low. However, DEXseq removes the exon level 
changes in expression to highlight differential exon usage of the gene. The exons shown in 
purple presented with significant differential exon usage (bottom panel, bin E014, E040 and 
E042), suggesting potential AS events (Figure 2B). The comparisons of each exon expression 
between tumour and normal samples were performed by normalisation counts, shown in Figure 
2C. 
We identified 27 novel transcript variants of the LEPROT gene (Table 2), 26 of those transcripts 
have statistically significant (FDR < 0.05) different exon usage. This suggests that different 
isoforms use the exons differently. One transcripts (E037) identified as having different exon 
usage was subsequently shown to be non-significant (FDR > 0.05, highlighted in red in Table 2). 
As visualised in Figure 2A and listed in Table 2, 5 transcripts of LEPROT demonstrated 
overexpression in the tumour samples, while 22 transcripts (21 significant / 1 non-significant) 
presented with overexpression in the normal samples. Decrease expression of LEPROT 
transcripts in tumour samples eventually downregulates general LEPROT expression in tumour 
samples. 
Discussion
The limiting factor in improving treatment for OS is a lack of understanding of the molecular 
mechanism of the disease, which leads to an inability to diagnose and treat OS at an earlier stage, 
or to develop more effective therapies. RNA-seq can be a potentially powerful method to 
identify differential exon usage in OS and allow identification of potential biomarkers of the 
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disease.27 Differential usage of exons produces different transcripts from the same gene.18 
Cancerous cells can have alternate patterns of exon usage within individual genes compared to 
normal cells, suggesting that AS may play a key role in shaping the phenotype of the tumour.23  
In this study, we have investigated AS events in 18 paired normal -tumour OS samples. 
Interestingly, our results showed that the LEPROT gene underwent AS and identified 26 
statistically significant (FDR < 0.05) novel transcripts. These transcripts showed different 
expression levels between tumour and normal tissues, suggesting there is a potential functional 
association between AS of LEPROT and cancer progression.
A genome-wide expression analysis has suggested an association between LEPROT regulation 
and apoptosis pathway.37 Unfortunately, the study did not explain the association further. 
However, the manifestations of LEPROT gene mutations have not been extensively studied, 
resulting in an incomplete understanding of the function or dysfunction of this gene in cancer 
metabolism.38 
LEPROT is expressed widely in many human tissues, but does not appear to be expressed in 
tumours.39 Therefore, loss or frequent downregulation of LEPROT expression could be 
associated with tumour formation. The cause of downregulation of the LEPROT gene in cancer 
cells remains unknown. One study has suggested that AS can downregulate overall gene 
expression by tagging specific transcripts for degradation through the nonsense-mediated mRNA 
decay (NMD) surveillance pathway.40 NMD frequently controls the translation stage and 
degrades the transcripts if they contain a premature termination codon (PTC), which can arise 
from genetic mutations or AS.41, 42 Truncated proteins cannot function properly or could even be 
toxic to the body, therefore, the synthesis of truncated proteins can contribute to various cancer 
types.43 We therefore encourage further investigation of the regulation of LEPROT gene 
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expression in normal and tumour cells. Our analysis highlighted LEPROT transcripts as being 
significantly under-expressed in 21 out of 26 tumour samples. Decrease expression of LEPROT 
transcripts in tumour samples, eventually can lead to reduction of total LEPROT expression 
level. The 5 overexpressed transcripts (absolute value of log2 fold-change > 1) can be considered 
as the noise from overall downregulation of LEPROT gene in OS. Therefore, it can be argued 
that they are not specific to OS initiation and progression. LEPROT is encoded by LEP receptor 
(LEPR) gene and they share the first two 5'-UTR exons.44 Unsurprisingly, we previously 
identified significant downregulation of LEPR in OS.30 
Several studies have discussed the association between LEPROT expression level and growth 
hormone (GH) activity.44 GH stimulates the development of bone and cartilage in children and 
adolescents.45 It also has been associated with induction of Insulin-like growth factor 1 (IGF-1) 
and IGF-1 receptor (IGF-1R) gene expression, alterations in glucose metabolism and modulation 
of cell proliferation genes.46-48 IGF-1 is produced in the liver, stimulated by GH, and plays a 
main role in tissue growth and development.49-52 Higher circulating levels of IGF-1 have a 
profound impact on cell proliferation, differentiation, promotion of cellular longevity and 
inhibition of apoptosis.53, 54 Consequently, overexpression of IGF-1/IGF-1R have been 
implicated in tumour formation, angiogenesis and metastasis in various human cancer types, 
including OS.46-48, 53 According to one study, LEPROT is directly involved in a receptor-
mediated cell signalling pathway by regulating cell surface expression of growth hormone 
receptor (GHR) at the molecular level. The same study also suggested that silencing of LEPROT 
increases cell-surface expression of GHR in a mouse model.55 Thus, increasing GHR expression 
level will lead to higher circulating levels of IGF-1 and may eventually result in 
tumorigenesis.47-49, 53, 55 
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Dysregulation of LEPROT is associated with various bone inflammation diseases in humans 
through the key inflammatory cytokines such as tumour necrosis factor alpha (TNF α) and 
interleukin 6 (IL-6). Several studies have highlighted that bone inflammation is a frequent 
precursor to initiation and progression of OS.56 Further, OS cells promote local inflammation and 
this leads to activation of local immune responses.57 Not surprisingly, upregulation of IL-6 and 
TNF-α have been observed in human OS cells.58, 59 In addition, IL-6 mediates tumour-host 
interactions that facilitate lung colonisation of metastasis-initiating by OS cells.60, 61 
Consequently, LEPROT may be implicated in OS initiation and metastasis through upregulating 
expression of IL-6 and TNF-α.
In conclusion, our data provide strong evidence that AS events of the LEPROT gene may be a 
risk factor for OS, and downregulation of LEPROT can be associated with tumorigenesis in 
bone. These results may facilitate a better understanding of the underlying molecular mechanism 
related to the initiation and progression of OS, thereby allowing identification of effective novel 
molecular target candidates for the treatment of the disease.
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Figure 1. Mean-Average (MA)-plot of normalised mean expression versus log2-fold change. 
The red marks represent the log of fold change versus average normalised count per exon that are 
significant (FDR <0.05). The red triangles represent exons with log2-fold change greater than 2 
or less than −2. The grey marks and triangles represent non-significant results.
Figure 2. DEXseq analysis on RNA-Seq data. The x -axis shows individual exons within 
LEPROT gene, whereas the y-axis represents exon expression (A), exon usage (B) and 
normalisation counts (C). The bars below the x -axis represent exons. The lines between the 
exons are introns. The numbers at the bottom are genomic locations of LEPROT. A highlights 
the fitted expression values of each of the exons of LEPROT gene for normal (red) and tumour 
(blue) samples. B visualises exon usage in the gene. The exon in purple (E014, E040 and E042) 
and 26 purple lines between the bars and exon names indicate a significant differential exon 
usage (FDR<0.05), whereas E037 revealed insignificant splicing (FDR>0.05). C shows the 
comparison of exon expression between the samples.
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Table 1. Characteristics of osteosarcoma patients in the present study (n= 18).
Patient Code Gender Age Site of tumour Stage Metastasis Chemotherapy
OSVN001 Female 16 Femur I No Yes
OSDN001 Male 23 Tibia III Yes Yes
OSVN003 Male 13 Femur I No Yes
OSVN004 Female 16 Femur I No Yes
OSVN005 Male 18 Femur I No Yes
OSVN006 Male 18 Femur I No Yes
OSVN008 Male 52 Femur I Yes No
OSHN008 Female 24 Tibia I No Yes
OSHN009 Male 16 Femur I No Yes
OSHN010 Female 20 Femur I No Yes
OSHN011 Male 7 Tibia I No No
OSHN012 Male 11 Humerus I No No
OSHN013 Male 17 Femur I No Yes
OSHN014 Female 16 Tibia III No Yes
OSVN015 Male 15 Tibia I No Yes
OSHN015 Female 8 Tibia I No Yes
OSHN016 Male 20 Femur I No Yes
OSHN017 Female 23 Humerus I No Yes
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Table 2. Differently spliced transcript variants of LEPROT.
*Normalised counts














ENSG00000213625.7+ENSG00000116678.17: E014 71.55 214.78 -1.59 3.03E-13 4.07E-08 65431803 65431920 118
ENSG00000213625.7+ENSG00000116678.17: E015 88.50 242.77 -1.49 2.74E-10 9.22E-06 65431921 65432064 144
ENSG00000213625.7+ENSG00000116678.17: E027 45.21 28.69 0.66 3.32E-09 4.25E-05 65608753 65608901 149
ENSG00000213625.7+ENSG00000116678.17: E032 46.70 27.21 0.78 4.39E-09 4.73E-05 65617964 65618146 183
ENSG00000213625.7+ENSG00000116678.17: E016 498.02 1229.84 -1.30 1.01E-08 7.57E-05 65432065 65436007 3943
ENSG00000213625.7+ENSG00000116678.17: E022 21.01 13.80 0.61 8.97E-09 7.57E-05 65596448 65596593 146
ENSG00000213625.7+ENSG00000116678.17: E036 17.21 10.89 0.66 1.10E-08 7.57E-05 65622906 65622981 76
ENSG00000213625.7+ENSG00000116678.17: E021 21.80 12.71 0.78 9.81E-09 7.57E-05 65592657 65592865 209
ENSG00000213625.7+ENSG00000116678.17: E019 33.89 20.33 0.74 1.29E-08 8.44E-05 65570473 65570802 330
ENSG00000213625.7+ENSG00000116678.17: E040 586.05 394.12 0.57 1.75E-08 0.00010921 65633152 65635409 2258
ENSG00000213625.7+ENSG00000116678.17: E009 6.97 19.68 -1.50 2.13E-08 0.00011916 65425303 65425378 76
ENSG00000213625.7+ENSG00000116678.17: E028 51.71 31.11 0.73 3.28E-08 0.00013701 65609947 65610106 160
ENSG00000213625.7+ENSG00000116678.17: E023 27.34 17.71 0.63 1.37E-07 0.00037999 65598660 65598804 145
ENSG00000213625.7+ENSG00000116678.17: E024 78.79 53.17 0.57 3.83E-07 0.00072278 65601392 65601682 291
ENSG00000213625.7+ENSG00000116678.17: E031 53.74 33.47 0.68 3.83E-07 0.00072278 65616008 65616224 217
ENSG00000213625.7+ENSG00000116678.17: E012 45.95 125.95 -1.45 4.18E-07 0.000759 65429931 65430048 118
ENSG00000213625.7+ENSG00000116678.17: E034 31.50 20.95 0.59 3.14E-06 0.00236337 65619940 65620023 84
ENSG00000213625.7+ENSG00000116678.17: E035 30.34 19.92 0.61 3.24E-06 0.00240758 65621353 65621458 106
ENSG00000213625.7+ENSG00000116678.17: E042 17.90 10.30 0.80 5.92E-06 0.00325498 65636191 65637102 912
ENSG00000213625.7+ENSG00000116678.17: E029 27.13 19.09 0.51 6.46E-06 0.00347045 65610214 65610268 55
ENSG00000213625.7+ENSG00000116678.17: E033 14.09 9.19 0.62 6.61E-06 0.00352845 65619928 65619939 12
ENSG00000213625.7+ENSG00000116678.17: E020 15.80 10.90 0.54 9.26E-06 0.00429905 65572326 65572449 124
ENSG00000213625.7+ENSG00000116678.17: E025 26.93 15.93 0.76 1.14E-05 0.00479061 65601843 65601960 118
ENSG00000213625.7+ENSG00000116678.17: E026 47.90 32.81 0.55 1.19E-05 0.00490364 65605038 65605237 200
ENSG00000213625.7+ENSG00000116678.17: E018 8.83 4.67 0.92 1.83E-05 0.00607585 65565546 65565605 60
ENSG00000213625.7+ENSG00000116678.17: E030 21.85 15.65 0.48 4.28E-05 0.00984627 65610269 65610296 28
ENSG00000213625.7+ENSG00000116678.17: E037 11.05 5.21 1.08 0.000784 0.05035195 65622982 65623384 403
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Figure 1. Mean-Average (MA)-plot of normalised mean expression versus log2-fold change. 
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